Code : 9345-331718      Created Date : Wednesday, October 23, 2013   Update Date : Wednesday, October 23, 2013    Visit : 2161

15th international congress of Immunology

The Report of 15th international congress of Immunology by Dr.Jamshid Hadjati
Application Code :
306-0213-0036
 
Created Date : Sunday, October 13, 2013Update Date : Sunday, October 13, 2013IP Address :194.225.51.101
Submit Date : Sunday, October 13, 2013Email : hajatij@tums.ac.ir
Personal Information
Name : Jamshid
Surname : Hadjati
School/Research center : Medicine
Possition : Professor
Tel : +21-64-53268
E-mail : hajatij@tums.ac.ir
Information of Congress
Title of the Congress : 15th international congress of Immunology
Title of your Abstract :

Comparison of monocyte derived dendritic cells versus leukemic

blasts derived dendritic cells for immunotherapy of AML

Venue : Milan/Italy
From : Thursday, August 22, 2013
To : Tuesday, August 27, 2013
Abstract(Please copy/paste the abstract send to the congress) : Background: Despite consolidation chemotherapy, relapse occurs in majority of patients with acute myeloid leukemia (AML) due to the presence of minimal residual disease. Dendritic cell (DC) based immunotherapy can help to maintain patients in remission. DCs can be generated from peripheral leukemic blasts (AML-DC) as well as peripheral blood monocytes(mo-DC). The aim of this study was to compare mo-DCs with AML-DCs in terms of maturation and functional properties. Methods: Isolated blasts from 15 AML patients and monocytes from 20 healthy donors were differentiated into DCs in the presence of rhGM-CSF and rhIL-4. Different TLR agonists were used for DC maturation. Generated DCs were compared for efficiency of production, percent of recovery, maturation and functional properties. Results: Results demonstrated that AML-DCs could be generated from 73% of patients versus 100% of that mo-DCs. Median recovery of mo-DCs was higher compared to AML-DCs. Also Mo-DCs showed higher expressions of surface molecules (HLA-DR, CD40, CD11c, CD83, CCR7 or CD86). However AML-DCs showed lower but reasonable capacity to stimulate allogeneic T cells in vitro as well as higher production of IL-12p70. Conclusion: Although production of AML-DC is not feasible in all patients, once generated can be used as a proper alternative in immunotherapy of patients in which production of mo-DCs is not possible.
Keywords of your Abstract : Dendritic cell, Monocyte, AML
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/11752/Forms/306/accept.docx
The presentation : Poster
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/11752/Forms/306/Cover.docx
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/11752/Forms/306/Abstract.docx
Where has your abstract been indexed? : Pubmed
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 5300
Delegates from which countries presented in the congress? : More than 20 different countries including Japan, USA, UK, Italy and....
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : IUIS
What were the responses to your talking points? Were specific questions or concerns raised? : I presented Poster and some participant asked some questions about the presented work. Also an american scientist (Bernard A. Fox, PhD, Chief, Molecular & Tumor Immunology Robert W. Franz Cancer Research Center Earle A. Chiles Research Institute
Providence Cancer Center Portland, OR) asked me some question about the situation of Tumor Immunotherapy in Iran and invited me to a meeting in Milan (World Immunotherapy Council Leadership meeting at ICI in Milan) and I introduced Iranian society for Immunology and Allergy as candidate organization for cooperation with WIC. I also asked him to attend in our next congress to evaluate for furthur cooperations.
If you met staff members, please list their full names & positions. : As I am the head of scientific committee of 12th congress of Immunology next year in Iran I met some delegates and invited them for our congress and our congress office is following the invitation now.
Please inform us if there are any follow up actions we need to talk with the members of the congress : No thanks. As I mentioned Our congress office will follow my preliminary negotiation. We also asked deputy of international affairs to cooperate with us in our upcoming congress(12th international congress of immunology and allergy of Iran).
I will paste the next answer here to fulfill the Job(450 character). Because I dont know which kind of follow up you can do with a congress which finished.
15th international congress of Immunology is the most important event in the world which is take place every 3 years. The congress was scheduled for 5 days and different kinds of meeting was planned for different audiences ( like plenary lectuers, workshopes, lunchtime lectures and so on). As I mentioned earlier I talked with some main lecturers in different sessions and invite them for our congress. Also I was able to take the opportunity to update my knowledge in different fields of Immunology. .
Your experiences about the travel processes(Providing ticket, accommodation,...) : I bought the ticket from Iran Air without any more discount besides our previously obtained and used internet booking without any problems
Please give a briefing of your own observations and outcomes of the congress: : 15th international congress of Immunology is the most important event in the world which is take place every 3 years. The congress was scheduled for 5 days and different kinds of meeting was planned for different audiences ( like plenary lectuers, workshopes, lunchtime lectures and so on). As I mentioned earlier I talked with some main lecturers in different sessions and invite them for our congress. Also I was able to take the opportunity to update my knowledge in different fields of Immunology. There was also a great exhibition area in the congress base floor which different main companies (like BD, Milteny and ...)from various countries participated and I visited most of them and asked about their updated technologies and products in the field of Immunology.

 

Your Comments :
captcha
Close